ArticleNature medicine2018
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Terry J Fry et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
833 papers cite itlatest 60 shown
this paperpooled ittrialcites it